Sei Investments Co. Trims Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Sei Investments Co. lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 47.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,976 shares of the company’s stock after selling 34,505 shares during the period. Sei Investments Co. owned 0.05% of Kiniksa Pharmaceuticals worth $728,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Essex Investment Management Co. LLC boosted its stake in Kiniksa Pharmaceuticals by 0.5% in the 1st quarter. Essex Investment Management Co. LLC now owns 172,740 shares of the company’s stock worth $3,408,000 after purchasing an additional 850 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kiniksa Pharmaceuticals by 5.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock valued at $413,000 after acquiring an additional 1,153 shares during the period. SG Americas Securities LLC grew its stake in Kiniksa Pharmaceuticals by 8.1% during the first quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after acquiring an additional 1,435 shares in the last quarter. Linden Thomas Advisory Services LLC increased its holdings in Kiniksa Pharmaceuticals by 1.7% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company’s stock worth $2,209,000 after acquiring an additional 1,921 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in Kiniksa Pharmaceuticals by 7.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company’s stock worth $530,000 after acquiring an additional 1,940 shares during the period. 53.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total value of $437,325.00. Following the completion of the sale, the chief operating officer now owns 116,975 shares in the company, valued at approximately $2,923,205.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider John F. Paolini sold 22,000 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $26.32, for a total transaction of $579,040.00. Following the transaction, the insider now owns 47,803 shares in the company, valued at $1,258,174.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eben Tessari sold 17,500 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the completion of the transaction, the chief operating officer now directly owns 116,975 shares of the company’s stock, valued at approximately $2,923,205.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 278,064 shares of company stock valued at $7,165,254 over the last ninety days. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Stock Performance

Shares of Kiniksa Pharmaceuticals stock opened at $24.47 on Wednesday. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $14.12 and a 52-week high of $27.92. The company’s 50 day moving average price is $25.37 and its 200-day moving average price is $21.61. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 222.45 and a beta of 0.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. The business had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company’s revenue was up 51.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.02) EPS. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KNSA. Wedbush raised their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $33.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.